Introduction Radiation therapy (RT) is frequently used for post-operative treatment in breast cancer (BC) patients who received preoperative systemic therapy (PST) and surgery. Nevertheless, the optimal timing to start RT is unclear. Material and methods Data from BC patients who underwent chemotherapy as PST, breast surgery and RT at 3 Institutions in Brazil and Canada from 2008 to 2014 were evaluated. Patients were classified into three groups regarding to the time to initiation of RT after surgery: <8 weeks, 8–16 weeks and >16 weeks. Results A total of 1029 women were included, most of them (59.1%; N = 608) had clinical stage III. One hundred and forty-one patients initiated RT within 8 weeks, 663 between 8 and 16 weeks and 225 beyond 16 weeks from surgery. With a median follow-up of 32 months, no differences in disease-free survival (DFS), overall survival and locoregional recurrence-free survival (LRRFS) were observed of time to indicated RT (<8 weeks versus 8–16 weeks versus >16 weeks). However, in luminal subtype patients (46.5%; N = 478), initiation of RT up to 8 weeks after surgery was associated with better LRRFS (<8 weeks versus >16 weeks: HR 0.22; 95%CI 0.05–0.86; p = 0.03), with a tendency to a better DFS (<8 weeks versus >16 weeks: HR 0.50; 95%CI 0.25–1.00). Conclusion RT initiated up to 8 weeks after surgery was related to better LRRFS in luminal BC patients who underwent PST. Our results suggest that early start of RT is important for these patients.
The aim of this study was to evaluate a calcium phosphate cement (CPC) marker as an injectable nonmetallic fiducial marker. We investigated interfraction cervical motion with cone beam CT (CBCT) images using a CPC marker and marker visibility on T2-weighted MRI for cervical cancer patients. Materials/Methods: Our commercially available CPC, widely used as a bone substitute, was prepared by mixing a powder component and liquid. A volume of 0.1-0.2 cc of the paste was injected by a disposable syringe with a 19-gauge long needle. This paste was self-hardening and recrystallizes to calcium hydroxylapatite in a living body. Six patients received 3-4 injections of CPC paste placed at a depth of 10 mm into a tumor of the cervix before planning CT. Patients were first treated with external beam radiation therapy to the whole pelvis with a total prescribed dose of 48.6-50.4 Gy delivered in 27-28 fractions. Three fractionated highdose rate brachytherapy treatments were performed with a prescribed dose per fraction of 6 Gy to Point A. Concurrent chemotherapy was delivered to all except one patient. In each fraction, a CBCT scan was acquired before dose delivery. Position verification was based on registration of the bony structures in the CBCT images corresponding to planning CT images. Systematic and random displacement of the marker centroid analysis was performed in 3 directions. Visibility of the markers using T2-weighted MRI before final brachytherapy was also assessed. Results: The procedure was well-tolerated. There was no interruption of the implantation due to pain or hemorrhage. There were no other procedure-related complications during or after CPC marker injection. Comparing the initial and final CBCT images, one patient had lost all three markers and one patient lost one marker. Gross tumor volumes (GTV) before radiation therapy of these patients were 250.7 and 91.7 cc, and GTV before final brachytherapy were 7.5 and 1.1 cc, respectively. The initial GTV of patients with no marker loss ranged from 49.1-67.2 cc, and GTV before the final brachytherapy ranged from 2.4-8.4 cc. Of 15 markers in the final CBCT images, 11 markers with a size >0.15 cc on planning CT images were visible on T2-weighted MRI. For CPC marker movement with rigid bony anatomy registration, the mean-of-means /systematic variation / random variation were 0.6/2.4/0.5, 1.5/4.6/1.9, and 3.4/2.6/1.1 mm for the left-right, anterior-posterior, and cranial-caudal directions, respectively. Conclusion: The injection of CPC paste into the cervix was feasible and safe. More than 0.15 cc of CPC paste was required to be visualized with T2-weighted MRI. For patients with a large cervical tumor, technical improvements in CPC marker placement are necessary.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.